Rittenhouse P A, Bakkum E A, Levy A D, Li Q, Carnes M, van de Kar L D
Department of Pharmacology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153.
J Pharmacol Exp Ther. 1994 Dec;271(3):1647-55.
The present study characterized the serotonin (5-HT) receptor subtypes mediating adrenal corticotropic hormone (ACTH) and corticosterone responses to 5-HT agonists in conscious rats. The 5-HT2A/5-HT2C agonist (+/-(-)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HC1 (DOI) increased plasma ACTH and corticosterone in a dose-dependent manner. The 5-HT2A/5-HT2C antagonist ritanserin (0.01 and 0.1 mg/kg sc) inhibited the DOI-induced increase in plasma ACTH, but not corticosterone. Low doses of spiperone (0.01 and 0.1 mg/kg sc) significantly reduced the ACTH response to DOI. Because spiperone has a higher affinity for 5-HT2A than 5-HT2C receptors, these data suggest that DOI stimulates ACTH secretion through 5-HT2A receptors. 5-methoxy-3-[1,2,3,4-tetrahydro-4-pyridinyl]-1H-indole (RU 24969) is a potent 5-HT1A/1B and moderate 5-HT2C agonist that also has been suggested to release 5-HT. However, p-chlorophenylalanine (PCPA) did not reduce the effect of RU 24969 on plasma ACTH, suggesting that RU 24969 only acts as a direct agonist. 6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid (LY53857) injected into the lateral cerebral ventricles (i.c.v.) inhibited the ACTH, but not corticosterone response to peripheral injection of RU 24969, suggesting that central 5-HT2A/2C receptors mediate the ACTH response. LY53857 injection (i.c.v.) also inhibited the effect of p-chloroamphetamine (i.c.v.) on plasma ACTH. However, the corticosterone response was not inhibited by LY53857, suggesting a distinct location of 5-HT receptors regulating corticosterone secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究对介导促肾上腺皮质激素(ACTH)和皮质酮对清醒大鼠5-羟色胺(5-HT)激动剂反应的5-HT受体亚型进行了表征。5-HT2A/5-HT2C激动剂(+/-(-)1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷盐酸盐(DOI)以剂量依赖的方式增加血浆ACTH和皮质酮水平。5-HT2A/5-HT2C拮抗剂利坦色林(0.01和0.1mg/kg皮下注射)抑制了DOI诱导的血浆ACTH升高,但未抑制皮质酮升高。低剂量的舒必利(0.01和0.1mg/kg皮下注射)显著降低了对DOI的ACTH反应。由于舒必利对5-HT2A受体的亲和力高于5-HT2C受体,这些数据表明DOI通过5-HT2A受体刺激ACTH分泌。5-甲氧基-3-[1,2,3,4-四氢-4-吡啶基]-1H-吲哚(RU 24969)是一种强效的5-HT1A/1B和中度的5-HT2C激动剂,也被认为可释放5-HT。然而,对氯苯丙氨酸(PCPA)并未降低RU 24969对血浆ACTH的作用,这表明RU 24969仅作为直接激动剂起作用。注射到侧脑室(脑室内)的6-甲基-1-[1-甲基乙基]麦角林-8-羧酸(LY53857)抑制了ACTH对RU 24969外周注射的反应,但未抑制皮质酮反应,这表明中枢5-HT2A/2C受体介导ACTH反应。LY53857注射(脑室内)也抑制了对氯苯丙胺(脑室内)对血浆ACTH的作用。然而,皮质酮反应未被LY53857抑制,这表明调节皮质酮分泌的5-HT受体位置不同。(摘要截短至250字)